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Background: The epidermal growth factor receptor (EGFR) is an established target for anti-cancer treatment in
different tumour types. Two different strategies have been explored to inhibit this pivotal molecule in epithelial
cancer development: small molecules TKIs and monoclonal antibodies. ErbB/HER-targeting by monoclonal
antibodies such as cetuximab and trastuzumab or tyrosine-kinase inhibitors as gefitinib or erlotinib has been proven
effective in the treatment of advanced NSCLC.
Results: In this study we explored the potential of combining either erlotinib with cetuximab or trastuzumab to
improve the efficacy of EGFR targeted therapy in EGFR wild-type NSCLC cell lines. Erlotinib treatment was observed
to increase EGFR and/or HER2 expression at the plasma membrane level only in NSCLC cell lines sensitive to the
drug inducing protein stabilization. The combined treatment had marginal effect on cell proliferation but markedly
increased antibody-dependent, NK mediated, cytotoxicity in vitro. Moreover, in the Calu-3 xenograft model, the
combination significantly inhibited tumour growth when compared with erlotinib and cetuximab alone.
Conclusion: Our results indicate that erlotinib increases surface expression of EGFR and/or HER2 only in EGFR-TKI
sensitive NSCLC cell lines and, in turns, leads to increased susceptibility to ADCC both in vitro and in a xenograft
models. The combination of erlotinib with monoclonal antibodies represents a potential strategy to improve the
treatment of wild-type EGFR NSCLC patients sensitive to erlotinib.
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The epidermal growth factor receptor (EGFR, ErbB1,
HER1) is the prototypic member of the ErbB family of
receptor tyrosine kinases (TKs), which further consists
of ErbB2-4 (HER2-4). The ErbB receptors share a similar
protein structure, consisting of an extracellular ligand
binding domain, a single transmembrane domain and an* Correspondence: roberta.alfieri@unipr.it
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reproduction in any medium, provided the orintracellular C-terminal domain with tyrosine kinase
activity [1]. Upon specific binding of EGF-like ligands to
the extracellular domain, ErbB receptors dimerize, either
as homo- or heterodimers, and undergo autophosphory-
lation at specific tyrosine residues within the intracellu-
lar domain. The phosphorylated tyrosines serve as
docking sites for adapter molecules, such as Grb2 and
the p85 subunit of PI3K, which activate a complex
downstream network. The activated signaling pathways,
including the Ras/MAPK, Akt/mTOR kinase and STAT
cascades, in turn regulate transcription factors and other
proteins involved in cell proliferation, survival, motilityral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ErbB receptors have been developed: small-molecule
inhibitors of the tyrosine kinase domain (EGFR tyrosine
kinase inhibitors [TKIs], such as erlotinib and gefitinib),
and monoclonal antibodies (such as cetuximab, anti-
EGFR and trastuzumab, anti-HER2), directed against the
extracellular domain, which inhibit phosphorylation/
activation and promote internalization. EGFR and HER2
are overexpressed in 40-80% and 25-30%, respectively, of
non-small cell lung cancer (NSCLC) patients and their
overexpression has been frequently correlated with a
poor prognosis [3,4].
Erlotinib is an effective treatment for NSCLC patients
and has been registered as a second and third-line treat-
ment of NSCLC regardless of EGFR mutation status [5].
Gefitinib has been registered for the therapy of
advanced NSCLC harbouring activating EGFR mutations
in the tyrosine kinase domain, the most frequent being
L858R in exon 21 and Del (746–750) in exon 19 [6].
Although mutations in EGFR are useful predictors for
the activity of EGFR-TKI, they cannot be used as the
only criterion to determine who should receive anti-
EGFR therapy and it is becoming increasingly clear that
even patients with EGFR wild-type can benefit from
EGFR-TKI [5,7,8].
Cetuximab is a chimeric IgG1 monoclonal antibody
(mAb) that blocks ligand binding to EGFR, leading to a
decrease in receptor dimerization, autophosphorylation,
and activation of signaling pathways [9]. In addition the
binding of cetuximab initiates EGFR internalization
and degradation which leads to signal termination.
Moreover, unlike EGFR-TKIs, cetuximab can induce
antibody dependent cellular cytotoxicity (ADCC)
activity, an important immunologic antitumour effect.
Cetuximab in combination with chemotherapy has
been approved by the FDA for the treatment of meta-
static colorectal cancer and of locally advanced head
and neck cancer.
Two randomized phase III trials in NSCLC patients,
evaluating cetuximab in addition to first-line chemo-
therapy, showed a small benefit in overall survival for
the experimental treatment, which was considered in-
sufficient by the EMA for marketing approval [10,11].
However, a subgroup analysis of the FLEX phase III
trial recently demonstrated a larger survival benefit
from the experimental treatment in patients with high
immunohistochemical EGFR expression [12].
Trastuzumab, registered for the treatment of HER2
positive breast cancer, has also been tested in phase II
trials as a single agent and in combination with cytotoxic
chemotherapy for patients with NSCLC. These trials
have not yet produced any convincing evidence of an
improved antitumour activity by adding trastuzumab to
standard chemotherapy in NSCLC [13,14].Several preclinical studies on cell lines from different
tumour types, indicated that the association between
EGFR/HER2 mAbs with TKIs displays an increased effi-
cacy [15].
In this study we explored the potential of combining
erlotinib with either cetuximab or trastuzumab in order
to improve the efficacy of EGFR targeted therapy in
EGFR wild-type sensitive NSCLC cell lines. Our results
indicate that EGFR-TKI increases surface expression of
EGFR and/or HER2 only in erlotinib sensitive NSCLC
cell lines and, in turns, leads to increased susceptibility
to ADCC both in vitro and in xenograft models.
Results
Differential effects of erlotinib on EGFR and HER2
expression in sensitive and resistant NSCLC cell lines
Firstly, we evaluated the effect of erlotinib on total EGFR
and HER2 protein levels in sensitive NSCLC cell lines
(Calu-3, H322 and H292 cell lines carrying wild-type
EGFR; PC9 and HCC827 carrying EGFR E746-A750del
mutation) and in resistant cell lines (A549, H1299,
H1703 and Calu-1 intrinsically resistant carrying wild-
type EGFR; HCC827GR5 with MET amplification as
mechanism of acquired resistance to TKI) [16]. As
shown in Figure 1A, erlotinib induced accumulation of
EGFR protein in Calu-3 and H322 cells while HER2
accumulated in H322, H292, PC9 and HCC827 cells in a
dose-dependent manner. The EGFR/Actin and HER2/
Actin ratios obtained after treatment at 1 μM or 10 nM
erlotinib were calculated and values expressed as fold
differences versus control (Figure 1B). In contrast, EGFR
and HER2 protein accumulation was not observed in
any cancer cell line with intrinsic resistance to EGFR
inhibitors until the concentration of 10 μM. Indeed the
ratios EGFR/Actin or HER2/Actin were similar or even
lower than those calculated in untreated cells (Figure 1C)
and similar results were obtained with gefitinib (not
shown). A representative Western blotting of resistant
H1299 cell line is reported in Figure 1D.
The different effect of TKIs on HER2 expression be-
tween sensitive and resistant NSCLC cell lines was con-
firmed in the HCC827 parental and in the HCC827GR5
resistant clone treated for 48 h with gefitinib (Figure 1E).
Erlotinib increases the cell surface expression of EGFR
and HER2 in erlotinib sensitive NSCLC cell lines
EGFR and HER2 expression on the plasma membrane
was quantified by flow cytometry in sensitive EGFR
wild-type NSCLC cell lines Calu-3, H322 and H292 after
exposure to 1 μM erlotinib for 24 h. The drug enhanced
surface expression, calculated as molecules of equivalent
soluble fluorophore, of EGFR in Calu-3 (Figure 2A) and
H322 (Figure 2C, 2D) and of HER2 in H292 (Figure 2B)
and H322 (Figure 2C, 2D) cell lines. In H322 cell line,
Figure 1 (See legend on next page.)
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Figure 1 Erlotinib induces EGFR and HER2 protein accumulation only in sensitive NSCLC cell lines. (A) Calu-3, H322, H292, PC9 and
HCC827 cell lines were treated with the indicated concentrations of erlotinib for 48 h. At the end of the drug treatment cell lysates were
immunoblotted to detect the indicated proteins. The immunoreactive spots were quantified by densitometric analysis, ratios of EGFR/Actin and
HER2/Actin were calculated at 1 μM erlotinib for Calu-3 H322 and H292 or 10 nM for PC9 and HCC827 and values are expressed as fold increase
versus control (B). (C) HCC827GR5, A549, H1299, H1703, Calu-1 cell lines were treated with 1 μM erlotinib for 48 h and at the end of treatment
cell lysates were immunoblotted to detect the indicated proteins. The immunoreactive spots were quantified by densitometric analysis, ratios of
EGFR/Actin and HER2/Actin were calculated and values are expressed as fold increase versus control. (D) Representative Western blotting of
resistant H1299 cell line exposed to increased concentration of erlotinib. (E) HCC827 parental cell line and HCC827GR5 resistant clone were
treated with the indicated doses of gefitinib and processed as above. The results are from representative experiments. Each experiment, repeated
three times, yielded similar results.
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dose and time dependent (Figure 2C, 2D). Western blot
analysis of isolated cell surface membrane proteins (inset
Figure 2A) confirmed the increase of EGFR in erlotinib
treated Calu-3 cells.
Exploiting the ability of cetuximab and trastuzumab to
bind EGFR and HER2, we used these mAbs as primary
antibodies for flow cytometry analysis. By this approach,
as shown in Figure 3, we confirmed that the surface
density of cetuximab and trastuzumab-binding sites, re-
spectively, on Calu-3 (Figure 3A), H322 (3B) and H292
(3C) cells were increased after 1 μM erlotinib treatment.
These results suggest that erlotinib enhanced cell surfaceFigure 2 EGFR and HER2 increase at the plasma-membrane level. Calu
24 h, H322 cell line was treated with increasing concentration of erlotinib (
end of the treatment, cell surface expression of EGFR and/or HER2 were ev
Molecules of Equivalent Fluorophore [MEF] or as fold increase versus untre
protein membrane level in Calu-3 after treatment with 1 μM erlotinib for 2
proteins were pulled down with neutrAvidin beads. The results are from re
yielded similar results.expression of EGFR or HER2 on sensitive NSCLC cells,
leading to an increase of mAbs binding to cancer cell
surface.
Erlotinib induces EGFR protein stabilization
The possibility that the higher EGFR level observed in
Calu-3 cells exposed to erlotinib was due to protein
stabilization or increased synthesis was then explored.
As shown in Figure 4A, EGFR level increased after 2 h
of erlotinib treatment and reached a plateau after 24 h.
Furthermore, the maximum level was maintained during
time in the presence of the drug. However, after 48 h of
erlotinib removal, EGFR expression was reduced to level-3 (A) and H292 (B) cell lines were treated with 1 μM erlotinib for
C) or with 1 μM erlotinib for the indicated period of time (D). At the
aluated by flow cytometry and the quantification is reported as
ated control cells (D). Inset Figure 2A: Western blot analysis of EGFR
4 h. Whole cells were labeled with biotin and membrane bound
presentative experiments. Each experiment, repeated three times,
Figure 3 Erlotinib induces the increase of cetuximab and trastuzumab binding sites. Calu-3, H322 and H292 cell lines were treated with
erlotinib for 24 h. Binding sites were assessed by flow cytometry using cetuximab (Calu-3, H322) and trastuzumab (H292) as primary antibodies
followed by PE-anti-human IgG exposure. Binding sites quantification is reported as Molecules of Equivalent Fluorophore [MEF]. The results in A,
B, C are from representative experiments. Each experiment, repeated three times, yielded similar results.
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also treated with erlotinib in the presence of specific
inhibitors of mRNA (Actynomicin D) and protein
(Cycloheximide) synthesis. As shown in Figure 4C, the
erlotinib- induced EGFR protein increase was neither
influenced by Actynomicin D nor Cycloheximide treat-
ment indicating that the higher level of EGFR after erlo-
tinib treatment could be ascribed to post-transcriptionalFigure 4 Erlotinib induces EGFR protein accumulation through protei
of time with 0.5 μM erlotinib. At the end of drug treatments cell lysates we
treated with 0.5 μM erlotinib for 24 h then the drug was removed and dru
were immunoblotted to detect the EGFR protein levels. (C) Calu-3 cells we
0.1 μg/ml actynomicin D and 2 μg/ml cyclohexymide. At the end of the ex
proteins. The immunoreactive spots were quantified by densitometric anal
fold increase versus control. (D) Calu-3 cells were exposed to 0.5 μM erlotin
by RT-PCR. The mean values of two independent measurements (± SD) are
Western blotting in Calu-3 cells untreated or treated for 24 h with 1 μM ge
μM NVP-BKM-120 and NVP-BYL-719 and 100 nM RAD001. The results are fr
yielded similar results.mechanisms such as protein stabilization. Moreover, we
analyzed EGFR transcript level by real time PCR after
erlotinib treatment (Figure 4D). Erlotinib did not affect
EGFR mRNA level when compared to untreated cells.
With the aim to clarify why the increased level of
EGFR was induced only in sensitive cells, we then tested
the effect of EGFR inhibitors (gefitinib, erlotinib, cetuxi-
mab, lapatinib) and of inhibitors of MAPK and PI3K/n stabilization. (A) Calu-3 cells were treated for the indicated period
re immunoblotted to detect EGFR protein. (B) Calu-3 cells were
g-free medium was added for further 24 and 48 h. Then, cell lysates
re treated for 24 h with erlotinib 0.5 μM, in the absence/presence of
periment, cell lysates were immunoblotted to detect the indicated
ysis, ratios of EGFR/Actin were calculated and values are expressed as
ib for the indicated period of time and the EGFR mRNA was detected
shown. (E) EGFR, p-P70S6K, p-P44/42 and P44/42 were detected by
fitinib, erlotinib and lapatinib, 10 μg/ml cetuximab, 10 μM U0126, 1
om representative experiments. Each experiment, repeated three times,
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accumulation in Calu-3 cell line. Gefitinib, erlotinib,
lapatinib significantly inhibited the phosphorylation of
p70S6K and p44/42 and induced a significant increase in
EGFR protein level (Figure 4E). The MEK inhibitor
U0126 strongly enhanced EGFR expression, in contrast
no increase in the EGFR level was observed after incuba-
tion with the inhibitors of PI3K/AKT/mTOR pathway
tested (NVP-BKM-120 and NVP-BYL-719 PI3K inhibi-
tors and RAD001 mTOR inhibitor).
Effects of erlotinib and cetuximab combined treatment
on NSCLC cell growth and antibody-dependent
cell-mediated cytotoxicity
We then investigated the effect of targeting EGFR by
both the TKI erlotinib and the mAb cetuximab in a cell
viability assay (Figure 5). We treated Calu-3, H322 and
H1299 cells with erlotinib, cetuximab (doses ranged
from 1 to 50 μg/ml) or the combination based on the
schedule erlotinib 24 h followed by the combination of
erlotinib with cetuximab for 72 h. As expected Calu-3
(Figure 5A) and H322 (Figure 5B) cells were responsive
to erlotinib and cetuximab treatment, whereas H1299Figure 5 Effect of erlotinib and cetuximab combination on cell viabili
resistant cells (C) were exposed to the indicated concentrations of erlotinib
the combination of erlotinib and cetuximab for 72 h. After the treatments,
inhibition of cell viability versus control cells and are mean values of three(Figure 5C) cells were resistant to both the single regi-
mens. Comparing the experimental combination points
with that expected by the Bliss criterion, an additive
effect was observed only in the Calu-3 cells. In fact, in
the H322 cells we failed to observe any improvement
treating cells with the combined treatment and H1299
remained resistant.
Moreover, cell death, evaluated by morphological ana-
lysis, caspase-3 activation and cleavage, was negligible
under any of the tested treatments at all the time points
analyzed (not shown) suggesting that the combined
erlotinib-cetuximab treatment exerted a cytostatic and
not a cytotoxic effect.
Since the engagement of immune component system
is one of the main mechanisms of the activity of specific
mAbs directed to ErbB family members in vivo, we
examined whether erlotinib could enhance cetuximab-
or trastuzumab-mediated ADCC by NK cells. As shown
respectively in Figure 6 A-B cetuximab-dependent cyto-
toxicity in the presence of IL-2 activated NK cells was
higher in Calu-3 and H322 cells previously treated with
erlotinib compared with cells treated with cetuximab
alone. Similarly, trastuzumab-dependent cytotoxicity wasty in NSCLC cell lines. Calu-3, H322 sensitive cells (A, B) and H1299
for 96 h or cetuximab for 72 h and to erlotinib for 24 h followed by
cell viability was assessed by MTT assay. Data are expressed as percent
separate experiments (**P < 0.01 ***P < 0.001).
Figure 6 Erlotinib potentiates antibody dependent cell cytotoxicity. The indicated human NSCLC cell lines were treated with 1 μM erlotinib
for 24 h. After the treatment with erlotinib, 10 μg/ml Cetuximab (A, B, E) or Trastuzumab (C, D) were added to cancer cells seeded with
100 U/ml IL-2 activated-NK cells at the ratio of 1:25 and 1:50. After 4 h LDH release was determined as described in Methods section. The results
are from representative experiments. The experiment, repeated three times, yielded similar results (**P < 0.01 ***P < 0.001).
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treated with erlotinib compared with cells treated with
trastuzumab alone.
On the contrary, the combination of erlotinib with cetux-
imab did not significantly modify the mAb dependent cyto-
toxicity in H1299 resistant cancer cells.Figure 7 Antitumour activity of erlotinib and cetuximab on Calu-3 xe
and implanted s.c. (right flank) on female BALB/c-Nude mice. Tumours wer
treatments started when tumours reached an average volume of 300 mm3
i.p. twice weekly), or erlotinib plus cetuximab were administered for the du
volume ± SEM of 6 mice per group. (**p < 0.01, ***p < 0.001 vs control; #p <
followed by Bonferroni post-test).Effect of erlotinib and cetuximab on Calu-3 xenografts
To extend our results in vivo, we tested the combination
of erlotinib with cetuximab in a Calu-3 xenograft model
(Figure 7). When tumours were well established (14 days
post-injection, average volume of 300 mm3) mice
were randomized into four treatment groups receivingnografts. Calu-3 cells were suspended in matrigel and sterile PBS (1:1)
e allowed to establish growth after implantation for 14 days, and the
. Vehicle, erlotinib (25 mg/Kg, orally 5 days/week), cetuximab (2 mg/Kg
ration of the study. Data are expressed as percent change in tumour
0.05, ###p < 0.001 vs erlotinib; §p < 0.05 vs cetuximab; two-way ANOVA
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vehicles as described in the Methods section. Drug
treatments were well tolerated, and no signs of tox-
icity were detected during the study. The treatment
with either erlotinib or cetuximab as single agent delayed
tumour growth. However, the significance of the treatment
versus the control was observed only with cetuximab as
single agent or in combination. Interestingly, the treat-
ment with the combination of erlotinib plus cetuximab
significantly inhibited tumour growth when compared to
both the single agent treatments.
The histologic analysis of tumour samples showed that
the subcutaneous injection of Calu-3 strikingly reproduced
within four weeks the morphological features of human
adenocarcinoma (Figures 8A, 8B1-4, 8C-1). Neoplastic epi-
thelial cells clearly expressed cytokeratin (Figure 8C-2) and
were organized in secretory glands surrounded by cellular-
ized collagen as evidenced by Masson’s trichrome staining
(Figure 8C-4). Regressive phenomena and changes in size
of neoplastic glands together with intense stromal reaction
were observed in histologic samples of tumours fromFigure 8 Hystological analysis of tumours. A: Selected examples of H&E
induced by Calu-3 injection in untreated (C) and erlotinib (Erl), cetuximab (
(scale bars: 1 mm). Higher magnification of the same samples are shown o
morphological details of the control neoplastic epithelium (1, H&E) express
epidermis (arrowhead). The presence of inflammatory interstitial cells in a c
(bluish) surrounding neoplastic glands (purple) in a Erl + Cet treated tumou
illustrating the quantitative measurements of neoplastic, inflammatory cells
**p < 0.01, vs control; #p < 0.05, ##p < 0.01 vs erlotinib; §p < 0.05 vs cetuximatreated mice. Interestingly, cetuximab clearly resulted in
dense inflammatory periglandular infiltrates mostly com-
posed of lymphocytes (Figure 8C-3). Thus, the real impact
of treatment on tumour mass within the nodules was
assessed by the morphometric analysis of tissue compos-
ition. By this quantitative approach, in agreement with
gross anatomic measurements, we documented that the
combination of erlotinib with cetuximab was the most ef-
fective treatment on tumour growth inhibition (Figure 8D).
This contention was further supported by the
immunofluorescence analysis of Ki67 labelling on tumour
tissues at the end of the experimental protocol (Figure 9).
Erlotinib was able to reduce proliferation of neoplastic
cytokeratinpos cells only in association with cetuximab
whereas cetuximab had a negative impact on cycling cells
also as individual agent. The TUNEL assay indicated that,
according with in vitro data, apoptosis was not a signifi-
cant ongoing cellular event implicated in the effect of dif-
ferent treatments.
We have calculated that 0.026+/−0.016% neoplastic
cells were undergoing apoptosis in untreated tumours.stained sections of the entire subcutaneous xenografted tumour
Cet) or erlotinib + cetuximab (Erl + Cet) treated BALB/c nude mice
n corresponding panels in B (scale bars: 500 μm). C: representative
ing cytokeratin (2,* brown-immunoperoxidase) that also depicts the
etuximab treated tumour (3, H&E) and the intense collagen deposition
r (4, Masson’s trichrome) are shown (scale bars: 100 μm). D: Bar graphs
and stromal compartments composing the tumours. (*p < 0.05,
b).
Figure 9 Immunohistochemical analysis of cellular proliferation. Immunofluorescence images of Ki67 (green) nuclear labelling of cytokeratin
(CK, red) positive neoplastic cells in sections of xenografted tumours from an untreated (A) and Erl + Cet treated (B) BALB/c nude mouse. C: bar
graph illustrating the effect of the different treatments on the percentage of cycling (Ki67pos) neoplastic cells within the tumour. CTRL: untreated,
ERL: erlotinib, CET: cetuximab, COMB: erlotinib + cetuximab. * p < 0.01 vs CTRL.
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Cetuximab single treatment whereas Erl + Cet increased
the amount of TUNEL positive neoplastic cells although
reaching a rate of 0.12+/−0.03%. However, we cannot ex-
clude that apoptotic cell death may have contributed to
the positive effect of tumor shrinkage at earlier times
after drug administration.
Thus, these experimental observations suggest that
targeting EGFR by the combination of small molecules
and antibodies increases the in vitro and in vivo anti-
proliferative activity of both individual agents and
seems to be a potent therapeutic strategy against
NSCLC.
Discussion
The potential for dual-agent molecular targeting of the
ErbB family, has been clearly demonstrated in pre-
clinical models and confirmed on the clinical setting for
HER2-targeting agents in breast cancer. However, little
is known about this therapeutic strategy for different
targets in other tumour types.
In our current study we demonstrated that the
combination of erlotinib with cetuximab or trastuzumab
may enhance the antitumour activity of EGFR-TKI in
NSCLC cell lines harbouring wild-type EGFR and in
xenograft models.
The efficacy of the association between an EGFR/
HER2 mAbs with TKIs has been documented inpreclinical studies in several cell lines originating from
different tumour types [15]. In EGFR wild-type H292
and A549 NSCLC cell lines, the combination of either
gefitinib or erlotinib with cetuximab was reported to en-
hance growth inhibition in comparison to single treat-
ment, particularly in the H292 gefitinib sensitive cell line
[17]. In the A549 cell line, expressing both EGFR and
HER2, the combination of gefitinib with trastuzumab
significantly inhibited cell growth and proliferation [18].
In Calu-3 xenograft models, the combined treatment of
erlotinib and pertuzumab showed an enhanced antitu-
mour activity [19].
A correlation between cetuximab efficacy and EGFR
expression has been reported in preclinical studies [20]
and recently confirmed in clinical trials. Thus, the phase
III FLEX study involving patients with advanced NSCLC
showed a strong correlation between high tumour EGFR
overexpression and the efficacy of adding cetuximab to
platinum based first-line chemotherapy [12].
The combination of a TKI and a mAb was explored as a
potential strategy to overcome acquired resistance to first-
generation EGFR-TKIs. Kim and colleagues demonstrated
that the combination of lapatinib with cetuximab over-
came gefitinib resistance due to the secondary T790M
mutation in NSCLC by inducing enhanced cytotoxicity
both in vitro and in vivo [21]. Furthermore, the association
of cetuximab with afatinib has been shown to be effective
to overcome T790M-mediated drug resistance [22].
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mab did not lead to a significant radiological response
in NSCLC patients with clinically defined acquired
resistance to erlotinib indicating that such strategy is
not sufficient to overcome acquired resistance to erlo-
tinib [23].
The mechanisms leading to an enhanced activity of
combining a TKI with a monoclonal antibody have
been ascribed, in other cancer cell models, either to a
more efficient inhibition of TK receptors [17] or to
an increased targeted receptors on plasma membrane
induced by TKIs [24,25]. Scaltriti et al. showed that
lapatinib enhanced the effects of trastuzumab by in-
ducing HER-2 stabilization and accumulation at the
cell surface of breast cancer cell lines [24], and
Mimura et al. reported that lapatinib induced accumu-
lation of HER-2 and EGFR on esophageal cancer cell
lines evoking trastuzumab- and cetuximab- mediated
ADCC [25].
ADCC, one of the killing mechanism of the immune
system mediated by Natural Killer cells, plays a pivotal
role in the anti-cancer effects exerted by mAbs. There-
fore, increasing the ADCC activity is an important
objective in the development of novel therapeutic
approaches.
It has been recently demonstrated that the EGFR inhi-
bitors gefitinib and erlotinib enhance the susceptibility
to NK cell mediated lysis of A549, NCI-H23 and SW-
900 lung cancer cell lines [26] by the induction of
ULBP1 (a ligand of the NK cell activation receptor
NKG2D). These data indicate that EGFR blockade could
not be the only mechanism of action of EGFR inhibitors
in vivo. The efficacy of these inhibitors in lung cancer
may be at least in part mediated by increased suscepti-
bility to NK activity. Moreover, cetuximab serves as a
potent stimulus for NK functions including INF-gamma
production [27] and is also associated with a comple-
ment –mediated immune response [28].
We here demonstrated that erlotinib induces an accu-
mulation of EGFR and/or HER2 protein at the plasma
membrane level only in TKI sensitive NSCLC cell lines
whereas, in resistant cells (both, intrinsic or MET
amplification-mediated acquired resistance), this en-
hancement was not observed. The anti-tumour effect of
drug combination was more evident in ADCC experi-
ments compared with cell viability experiments. In the
Calu-3 xenograft model, the combined treatment
resulted in a lower rate of tumour growth, suggesting
the involvement of NK activity as a determinant factor
to improve the efficacy of the combined treatment.
Moreover, regressive phenomena and changes in size of
neoplastic glands together with intense stromal reaction
were observed in histologic samples of tumours from
mice treated with cetuximab alone or the combination.The reason why EGFR inhibitors such as gefitinib,
erlotinib or lapatinib induce EGFR accumulation only in
sensitive cells could be ascribed to their ability to inhibit
signal transduction pathways downstream EGFR. The
constitutive activation of signaling pathways downstream
of EGFR (i.e. presence of RAS mutations) is indeed a
recognized mechanism of resistance against reversible
EGFR-TKIs [29]. The inhibition of the MAPK pathway
might represent a link between EGFR inhibition and
EGFR accumulation since U0126, a well known MEK1/2
inhibitor, induced EGFR accumulation in Calu-3 cells,
while none of PI3K/AKT/mTOR inhibitors tested was
effective. A correlation between MAPK pathway and
protein degradation by the ubiquitin system was
described for the pro-apoptotic BH3-only protein BIM,
indeed in the absence of MAPK activation, BIM protein
accumulated in the cell promoting activation of apop-
totic cell death [30].
Considering that EGFR TKIs, in particular erlotinib,
demonstrated to be effective only in a small percentage
of NSCLC patients not harboring EGFR mutations,
our preclinical results could support clinical trials on
the combinations of erlotinib and cetuximab or trastu-
zumab aiming to improve treatment efficacy. Although
the addition of cetuximab to erlotinib is insufficient to
overcome erlotinib resistance in EGFR-driven lung
adenocarcinoma [23], the clinical potential of dual-
agent molecular targeting of the EGFR in patients with
EGFR wild-type tumours remains to be elucidated and
may represents an interesting research area to be
pursued.
Conclusions
In this study we explored the potential of combining
erlotinib with cetuximab or trastuzumab in improving
the efficacy of EGFR targeted therapy in EGFR wild-type
erlotinib-sensitive NSCLC cell lines. Our results indicate
that erlotinib, through ERK inhibition, increases surface
expression of EGFR and/or HER2 only in erlotinib sensi-
tive NSCLC cell lines and in turn leads to increased sus-
ceptibility to ADCC both in vitro and in xenografts
models.
These data prompt future adequate clinical trials that
will give the ultimate proof of the utility of this com-
bined treatment for the care of NSCLC patients carrying
EGFR-wild type that are sensitive to TKIs.
Methods
Cell culture
The human NSCLC cell lines H322, H292, Calu-3, H1299,
A549, H1703 and Calu-1 were obtained from American
Type Culture Collection (Manassas, VA, USA) and were
cultured as recommended. The PC9, HCC827 and
HCC827GR5 cell lines were kindly provided by Dr P.
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All cells were maintained under standard cell culture
conditions at 37°C in a water-saturated atmosphere of 5%
CO2 in air. As previously reported [31] cells showing by
proliferation assays IC50 for erlotinib < 1 μM were consid-
ered sensitive (H322, H292, Calu-3, PC9, HCC827) while
cell lines with IC50 > 5 μM (H1299, A549, H1703, Calu-1,
HCC827GR5) were considered resistant.
Drug treatment
Erlotinib, gefitinib, cetuximab, trastuzumab and rituximab
were from inpatient pharmacy. RAD001, NVP-BKM-120
and NVP-BYL-719 were from Novartis.
Stock solutions of 20 mM drugs were prepared in
dimethylsulfoxide (DMSO) (with the exception of
mAbs), stored at −20°C and diluted in fresh medium for
use. The final concentration of DMSO never exceeded
0.1% v/v.
Western blot analysis
Procedures for protein extraction, solubilization, and
protein analysis by 1-D PAGE are described elsewhere
[32,33]. Fifty μg of proteins from lysates were resolved
by 7.5% SDS-PAGE and transferred to PVDF mem-
branes. Membranes were incubated with: 1:1000 rabbit
polyclonal anti-EGFR; 1:1000 rabbit mAb anti-HER2/
ErbB2; 1:1000 rabbit mAb anti-Phospho-p70S6K
(Thr421/Ser424); 1:1000 mouse mAb anti-Phospho-p44/
42 MAPK (ERK1/2); 1:1000 rabbit mAb anti-p44/42
MAPK (ERK1/2) (Cell Signaling Technology, Beverly,
MA, USA); 1:1000 mouse mAb anti- Transferrin Receptor
(Invitrogen Corporation, Camarillo, CA, USA); 1:3000
mouse mAb anti-Actin (Sigma–Aldrich, St Louis, MO,
USA). Blots were then washed and incubated with HRP-
anti-mouse or HRP-anti-rabbit antibodies at 1:20000 dilu-
tion (Pierce, Rockford, IL, USA). Immunoreactive bands
were visualized using an enhanced chemiluminescence
system (ImmobilionTM Western Cemiluminescent HRP
Substrate, Millipore USA).
Cell surface protein isolation
Calu-3 cells were grown in T75 flasks and treated with
0.5 μM erlotinib for 24 h. Cells were incubated with
EZ-LINK Sulfo-Biotin (Pierce) for 2 h at 4°C with gentle
rotation. The reaction was stopped by washing twice
with 25 mM Tris–HCl (pH 7.5) in PBS (phosphate-buf-
fered saline) and cells were scraped into ice-cold lysis
buffer (50 mmol/l HEPES, pH 7.0, 10% glycerol, 1% Tri-
tonX-100, 5 mmol/l EDTA (ethylenediaminetetraacetic
acid), 1 mmol/l MgCl2, 25 mmol/l NaF, 50 μg/ml leu-
peptin, 50 μg/ml aprotinin, 0.5 mmol/l orthovanadate,
and 1 mmol/l phenylmethylsulfonyl fluoride). Lysates
were centrifuged at 15000 g for 20 min at 4°C, and
supernatants were removed and assayed for proteinconcentration using the DC Protein assay (Bio-Rad, CA,
USA). A volume of 500 μl of lysis buffer containing
equal amount of proteins was incubated with UltraLink
Immobilized NeutrAvidin protein (Pierce) for 2 h at 4°C
with gentle rotation, washed three times with lysis buffer
before suspension in SDS (sodium dodecyl sulfate)-load-
ing buffer and then resolved by SDS-PAGE.
Flow cytometry
For the determination of EGFR and HER2 protein mem-
brane levels, NSCLC cell lines H322, Calu-3 and H292
were treated with 1 μM erlotinib for 24 h. One million
cells per condition were then incubated with Isotype
control Monoclonal Mouse IgG1/R-PE (Ancell IRP,
Bayport, MN, USA), PE mouse anti-Human EGFR
(Calu-3 and H322 cells) (BD Biosciences, San Josè, CA,
USA) or PE mouse anti-Human HER2 (H322 and H292)
(BD Biosciences). After the incubation the analysis was
performed with an EPICS-XL flow cytometer.
For the relative quantization of EGFR or HER2 bind-
ing sites, NSCLC cell lines H322, Calu-3, H292 were
treated with 1 μM erlotinib for 24 h. One million cells
were then dispensed for each condition and treated with
either 20 μg/ml rituximab (Isotype control), cetuxi-
mab (Calu-3 and H322) or trastuzumab (H292) for
1 h. After the incubation with PE-anti-human-IgG
(BD Biosciences), the analysis was performed with an
EPICS-XL flow cytometer.
The values of mean fluorescence intensity (MFI) were
converted in units of equivalent fluorochrome (MEF)
using the FluoroSpheres 6-Peak Kit (Dako, CA, USA).
Quantitative real-time PCR
Total RNA was isolated by the TRIzolW reagent (Invitrogen,
Carlsbad, CA, USA) and reverse transcribed as previously
described [33].
The transcript levels of EGFR gene were assessed
by Real-Time qRT-PCR on an iCycler iQ Multicolor
RealTime PCR Detection System (Bio-Rad, Hercules,
CA, USA).
Primers and probes included: EGFR-F (50-GCCTT
GACTGAGGACAGCA-30), EGFR-R (5-TTTGGGAAC
GGACTGGTTTA-3), EGFR-probe (50-FAM CTTCC
TCC30DQ); PGK1-F (50-GGAGAACCTCCGCTTTCAT-
30), PGK1-R (50-CTGGCTCGGCTTTAACCTT-30), PGK1-





T-30), HPRT-probe (50-FAM GCTGAGGA 30DQ).
The amplification protocol consisted of 15 min at
95°C followed by 40 cycles at 94°C for 20s and at 60°C for
1 min.
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using the geNorm algorithm for Microsoft ExcelTM
after normalization by expression of the control genes
[phosphoglycerate kinase1 (PGK1), ribosomal protein
L13 (RPL13) and hypoxanthine-guanine-phosphoribo-
syltransferase (HPRT)] and expressed in arbitrary
units (a.u.).MTT assay
The cells were seeded into 96-well plate in quadruplicate
and were exposed to various treatments. After 96 h,
100 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetra-
zolium bromide (MTT) solution (1 mg/ml, Sigma-
Aldrich) was added to each well and incubated. After
4 h, crystalline formation was dissolved with DMSO and
the absorbance at 570 nm was measured using the
microplate-reader 550 (BioRad).Isolation and culture of NK cells
Human PBMC were isolated from buffy coat of
healthy donors by using a Lympholyte-H density gra-
dient centrifugation (Cederlane Burlington, Ontario,
Canada). Highly purified CD56+ natural killer (NK)
cells were obtained by magnetic separation using the
NK Cell Isolation Kit and the autoMACS Separator
(Miltenyi Biotec, Cologne, Germany) according to the
user manual.
Purified NK cells were resuspended in culture medium
(RPMI 1640 without phenol red and supplemented with
heat inactivated 10% FCS, 50 U/ml penicillin, 50 U/ml
streptomycin, 2 mmol/l glutamine) plated and preincu-
bated at 37°C for up to 18 h in the presence of human
Interleukin-2 (IL-2, 100 U/ml, Miltenyi Biotec).ADCC assay
Antibody-dependent cell-mediated cytotoxicity (ADCC)
was measured with the CytoTox 96 non-radioactive
cytotoxicity assay (Promega, Madison, WI, USA) accord-
ing to manufacturer’s instructions. 2x103 Calu-3, H322,
H292 or H1299 cells were treated for 24 h with 1 μM
erlotinib, and then seeded with purified NK cells (ratio
of 1:25 and 1:50) in a 96-well plate and incubated with
10 μg/ml cetuximab or trastuzumab. After 4 hours the
lactate dehydrogenase (LDH) release was determined
and the percentage of cytotoxicity was calculated after
correcting for background absorbance values according
to the following formula:%Cytotoxicity¼ExperimentalEffector spontaneous
Target maximumTarget sTumour xenografts
All experiments involving animals and their care were
performed with the approval of the Local Ethical
Committee of University of Parma, in accordance with
the institutional guidelines that are in compliance with
national (DL116/92) and international (86/609/CEE)
laws and policies. Twenty-four Balb/c-Nude female mice
(Charles River Laboratories, Calco, Italy) were housed in
a protected unit for immunodeficient animals with
12-hour light/dark cycles and provided with sterilized
food and water ad libitum. At the time of xenograft es-
tablishment, mice were 8 weeks old and weighted ~20g.
200 μl of matrigel (BD Biosciences) and sterile PBS (1:1)
containing 1x107 Calu-3 cells, were subcutaneously
injected on the right flank of each mouse (using a 1 ml
syringe, needle G25). When tumour volume reached an
average size of 300 mm3, 14 days after injection, animals
were randomized into four groups and the treatment
started. After 4 weeks, mice were euthanized by cervical
dislocation and tumours collected for immunohisto-
chemistry and histological analysis.
Erlotinib (25 mg/Kg) was administered orally in 1%
methylcellulose, 0.2% Tween 80 in sterilized water
5 days/week. Cetuximab (2 mg/Kg) was intraperitoneally
injected in sterile saline solution 2 days/week. Control
group received both oral gavage of 1% methylcellulose,
0.2% Tween 80 in sterilized water 5 days/week and i.p.
injection of sterile saline solution (0.9%) 2 days/week.
Dosages of drugs were chosen halving the one used in
a previous study in NSCLC-xenograft models, in order
to avoid the complete inhibition of tumour growth by
the single agent treatment and to better highlight the
effect of erlotinib-cetuximab combination [19,34].
Tumour xenografts were measured twice a week,
tumour volume was determined using the formula:
(length x width2)/2. Final data are expressed as percent
of volume increase: (tumour volume/pre-treatment
tumour volume) x 100.Morphometric and immunohistochemical analysis of
tumour xenografts
Formalin fixed samples were embedded in paraffin. From
each tumour serial sections of 5 μm thickness were
obtained and stained with Haematoxylin and Eosin (H&E),
Masson’s Trichrome and for immunohistochemistry.
Morphometric analysis was performed in order to evaluate:
(a) the numerical density of neoplastic cells, (b) the volume
fraction of interstitial inflammatory cells, (c) the volumeTarget spontaneous
pontaneous
100
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apoptotic cells.
In particular, for each section stained with H&E, a
quantitative evaluation of tissue composition was per-
formed. To better define the fraction occupied by
neoplastic and non neoplastic cells, sections were
stained with pancytokeratin antibodies (monoclonal
mouse, 1:500, o.n. 4°C, Dako) revealed through biotin-
streptavidin-DAB system, as repeatedly described. The
numerical density (n/mm2) of pancytokeratin positive
neoplastic cells was computed.
In addition, cell proliferation and apoptotic death were
investigated by fluorescence microscopy. Thus, Ki67 label-
ing (rabbit polyclonal antibody, Vector) and the Terminal
deoxynucleotidyltransferase (TdT)–mediated dUTP nick
end labeling (TUNEL) assay (Roche Diagnostics, Italy) on
cytokeratinpos neoplastic cells were revealed by specific
fuorescent probes.
The area occupied by interstitial cells was expressed as
percentage of the total area explored. By the same ap-
proach, the volume fraction of fibrosis was calculated on
Masson’s Trichrome stained sections. To define the
volume fractions, the number of points overlying each
tissue components was counted and expressed as per-
centage of the total number of points explored.
All these morphometric measurements were obtained
with the aid of a grid defining a tissue area of 0.23 mm2
and containing 42 sampling points each covering an area
of 0.0052 mm2.
All these evaluations were performed on the entire
section of each tumour sample of each experimental
group of animals using an optical microscope (250X
final magnification).Statistical analysis
Statistical analyses were carried out using GraphPad
Prism version 5.0 software (GraphPad Software Inc.,
San Diego, CA, USA). Results are expressed as mean
values ± standard deviations (SD) for the indicated
number of independent measurements. Differences be-
tween the mean values recorded for different experi-
mental conditions were evaluated by Student’s t-test,
and P values are indicated where appropriate in the fig-
ures and in their legends. A P value <0.05 was consid-
ered as significant.
For in vivo studies comparison among groups was
made using analysis of variance (two-way ANOVA
repeated measures) followed by Bonferroni’s post-test.
Analysis was performed using Prism 5.0 (GraphPad Soft-
ware) and differences were considered significant when
P value was below 0.05. The nature of the interaction
between erlotinib and cetuximab was calculated using
the Bliss interaction model [35].Abbreviations
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